HLA
Kidney Cancer Immunotherapy Response Linked to Signature Reflecting HLA, Tumor Immune Activity
Researchers found an immune checkpoint blockade response signature in renal cell carcinoma that reflects tumor immune activity influenced by human leukocyte antigen features.
Lung Cancer Study Highlights Genetic Variants Involved in Immunosurveillance
Researchers used large-scale population data to link lower-than-usual lung cancer risk to increased heterozygosity in the human leukocyte antigen class II region.
COVID-19 Protection Provided by HLA Genetic Variant, Study Suggests
Using data from bone marrow registry participants, researchers found an HLA variant linked to symptom-free SARS-CoV-2 infection and better immune cell responses.
Tempus, TScan Therapeutics Partner on CDx for T-Cell Receptor Therapy in Solid Tumors
The companies will collaborate to develop a companion diagnostic to support TScan's screening protocol for its Phase 1 solid tumor clinical trial.
The company has identified numerous immunogenic peptides derived from transposable elements at the surfaces of cancer cells.